Skip to content

Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.

Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05206292
Acronym
PsyNIT
Enrollment
600
Registered
2022-01-25
Start date
2023-01-12
Completion date
2025-06-01
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inherited Metabolic Disorder of Nervous System, Schizophrenia

Keywords

NIT1, Sulfitest, Inherited Metabolic Disorder, Psychotic Disorders

Brief summary

Screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.

Detailed description

Psychotic disorder is a public health problem, with a cumulative incidence in the general population estimated at 3%. Although in most cases the origin is purely psychiatric, psychotic disorder can also represent a mode of entry into many organic pathologies. Among these, hereditary metabolic diseases, although rare in the general population, hold a special place, especially in view of their potentially treatable character. However, the identification of this type of disease within the mass of patients with psychotic disorders can be an extremely complex task, and has been the subject of scientific interest for many years. Recently, at the Grenoble Alpes University Hospital, a new hereditary metabolic disease that causes psychotic disorders has been discovered. This disease was identified in a family of patients, most of whom had psychotic disorders, and all of whom had deep cystic leukoencephalopathy on MRI and a positive sulfitest. The discovery of this new hereditary metabolic disease raises the question of its prevalence in patients with psychotic disorders, and more generally of the prevalence of diseases of sulfur amino acid metabolism. PsyNIT study therefore aims, using the sulfitest, to detect hereditary diseases of sulfur amino acid metabolism in a sample of patients with psychotic disorders without known organic etiology. The discovery of other patients would raise the question of screening more widely for this type of pathology, and would modify the management of the patients thus screened in terms of follow-up and possibly treatment.

Interventions

DIAGNOSTIC_TESTSulfitest

Urine strip to detect the presence of sulfites in urine. Immediate result.

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Adult patients with psychotic disorder without known organic cause.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female 18 years of age and older, * Followed for a psychotic disorder, * With no known organic etiology for the psychotic disorder, * Not having formulated its opposition to participation in the study (or his/her tutor/curator), * Affiliated with the social security system.

Exclusion criteria

* Patients protected by law (minors, pregnant or breastfeeding women, deprived of liberty or hospitalized under constraint, under administrative or judicial supervision) except patients under tutorship or curatorship.

Design outcomes

Primary

MeasureTime frameDescription
Number of positive sulfitests (compared to the number of patients included).15 minutesSulfitest is considered positive if clearly colored.

Secondary

MeasureTime frameDescription
Sulfite concentration in urine (semi-quantitative scale).15 minutesSulfite concentration is estimated by visual analysis of the urine dipstick test.
Clinical characteristics of patients with a positive sulfitest.15 minutesCollection of clinical characteristics of patients with a positive sulfitest, by questioning or by analysis of the medical record.

Countries

France

Contacts

Primary ContactGauthier Willaume
gwillaume@chu-grenoble.fr+33 4 76 76 57 92

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026